Boehringer Files Pradaxa Antidote, Could Lead To Reversible Novel Anticoagulant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Finishing off a rolling BLA, company believes that the specific antidote for its novel anticoagulant Pradaxa will be eligible for accelerated approval based on Phase I data in volunteers.
You may also be interested in...
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.